A Concise Review on Tyrosine Kinase Targeted Cancer Therapy

被引:0
作者
Shah, Ashish [1 ]
Patel, Chhagan [2 ]
Parmar, Ghanshaym [1 ]
Patel, Ashish [3 ]
Jain, Manav [4 ]
机构
[1] Sumandeep Vidyapeeth, Dept Pharm, Vadodara, Gujarat, India
[2] Shree Sarvajaink Pharm Coll, Mehsana, Gujarat, India
[3] CHARUSAT, Ramanbhai Patel Coll Pharm, Anand, Gujarat, India
[4] Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh, Punjab, India
关键词
Tyrosine kinase; types of receptors; tyrosine kinase inhibitors; cancer; small molecules; targeted therapy; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; METASTATIC COLORECTAL-CANCER; SRC FAMILY KINASES; OPEN-LABEL; BREAST-CANCER; DOUBLE-BLIND; 1ST-LINE TREATMENT; MOLECULAR TARGETS; THYROID-CANCER;
D O I
10.2174/1574885517666220331104025
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tyrosine Kinase (TK) is considered one of the important family members of the kinase family due to its important role in various cellular processes like cell growth, cell differentiation, apoptosis, etc. Mutation, overexpression, and dysfunction of tyrosine kinase receptors lead to the development of malignancy; thus, they are considered one of the important targets for the development of anti-cancer molecules. The tyrosine kinase family is majorly divided into two classes; receptor and non-receptor tyrosine kinase. Both of the classes have an important role in the development of tumour cells. Currently, more than 40 FDA-approved tyrosine kinase inhibitors are used to treat various types of cancers. Tyrosine kinase inhibitors mainly block the phosphorylation of tyrosine residue of the corresponding kinase substrate, so activation of downstream signalling pathways can be inhibited. The promising results of tyrosine kinase inhibitors in solid tumours have revolutionized oncology research. In this article, we summarized the role of some important members of the tyrosine kinase family in the development and progression of tumour cells and the significance of tyrosine kinase inhibitors in the treatment of various types of cancer.
引用
收藏
页码:96 / 107
页数:12
相关论文
共 118 条
  • [1] Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
    Ahn, Myung-Ju
    Han, Ji-Youn
    Lee, Ki Hyeong
    Kim, Sang-We
    Kim, Dong-Wan
    Lee, Yun-Gyoo
    Cho, Eun Kyung
    Kim, Joo-Hang
    Lee, Gyeong-Won
    Lee, Jong-Seok
    Min, Young Joo
    Kim, Jin-Soo
    Lee, Sung Sook
    Kim, Hye Ryun
    Hong, Min Hee
    Ahn, Jin Seok
    Sun, Jong-Mu
    Kim, Heung Tae
    Lee, Dae Ho
    Kim, Sohee
    Cho, Byoung Chul
    [J]. LANCET ONCOLOGY, 2019, 20 (12) : 1681 - 1690
  • [2] TGF-β receptors: In and beyond TGF-β signaling
    Ark, Alexandra Vander
    Cao, Jingchen
    Li, Xiaohong
    [J]. CELLULAR SIGNALLING, 2018, 52 : 112 - 120
  • [3] Advances and challenges in targeting FGFR signalling in cancer
    Babina, Irina S.
    Turner, Nicholas C.
    [J]. NATURE REVIEWS CANCER, 2017, 17 (05) : 318 - 332
  • [4] Kinase-targeted cancer therapies: progress, challenges and future directions
    Bhullar, Khushwant S.
    Orrego Lagaron, Naiara
    McGowan, Eileen M.
    Parmar, Indu
    Jha, Amitabh
    Hubbard, Basil P.
    Rupasinghe, H. P. Vasantha
    [J]. MOLECULAR CANCER, 2018, 17
  • [5] Structure and regulation of Src family kinases
    Boggon, TJ
    Eck, MJ
    [J]. ONCOGENE, 2004, 23 (48) : 7918 - 7927
  • [6] Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies
    Brahmkhatri, Varsha P.
    Prasanna, Chinmayi
    Atreya, Hanudatta S.
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [7] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    Brose, Marcia S.
    Nutting, Christopher M.
    Jarzab, Barbara
    Elisei, Rossella
    Siena, Salvatore
    Bastholt, Lars
    de la Fouchardiere, Christelle
    Pacini, Furio
    Paschke, Ralf
    Shong, Young Kee
    Sherman, Steven I.
    Smit, Johannes W. A.
    Chung, John
    Kappeler, Christian
    Pena, Carol
    Molnar, Istvan
    Schlumberger, Martin J.
    [J]. LANCET, 2014, 384 (9940) : 319 - 328
  • [8] The distinctive nature of HER2-positive breast cancers
    Burstein, HJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1652 - 1654
  • [9] A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14 - Recruitment of C-terminal Src kinase
    Cao, HM
    Courchesne, WE
    Mastick, CC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (11) : 8771 - 8774
  • [10] VEGF as a key mediator of angiogenesis in cancer
    Carmeliet, P
    [J]. ONCOLOGY, 2005, 69 : 4 - 10